apl. Prof. Dr. Peter Goebell

Medizinische Fakultät Urologische Klinik

Effect of Recipient Variables on Transplant Survival Following Marginal Kidney Donation: Analysis of a Mate Kidney Cohort (2025) Androvitsanea A, Heller KM, Apel H, Kunath F, Goebell P, Wullich B, Rother U, et al. Journal article Improving quality of care for cancer patients through oncological second opinions in a Comprehensive Cancer Center: adherence to second-opinion therapy recommendations (2025) Schulmeyer C, Fasching P, Beckmann M, Häberle L, Golcher H, Goebell P, Pöschke P, Emons J Journal article Change of the guards—Looking back at Michael Droller: Visionary and supporter—The perspective of the International Bladder Cancer Network (2025) Schmitz-Dräger B, Grossmann HB, Goebell P, Kamat AM, Black PC Journal article Correction to: Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis (Current Oncology Reports, (2024), 26, 12, (1639-1650), 10.1007/s11912-024-01613-7) (2025) Frazer R, Arranz JÁ, Estévez SV, Parikh O, Krabbe LM, Vasudev NS, Doehn C, et al. Journal article, Erratum Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN) (2025) Schmitz-Dräger BJ, Bismarck E, Ebert T, Starlinger R, Dienes K, Ottillinger B, Goebell P, et al. Journal article Contemporary real-world treatment in metastatic hormone-sensitive prostate cancer: US, four European countries, and UK (2025) Goebell P, Chen S, Jhaveri J Journal article Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial (2025) Powles T, Tagawa S, Vulsteke C, Gross-Goupil M, Park SH, Necchi A, De Santis M, et al. Journal article Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial (2025) Bergmann L, Albiges L, Ahrens M, Gross-Goupil M, Boleti E, Gravis G, Fléchon A, et al. Journal article PSA im Extrembereich – Ausdruck einer infausten Prognose? Eine Übersicht über Verlauf und Therapie des Prostatakarzinoms mit PSA-Werten (prostataspezifisches Antigen) im drei- bis vierstelligen Bereich (2025) Dirscherl C, Ebert T, Schmitz-Dräger BJ, Goebell P Journal article Androgenrezeptor-gerichtete Therapien – klinisch relevante Interaktionen vermeiden (2025) Lipp HP, Von Amsberg G, Merseburger AS, Rausch S, Schöning T, Klier J, Goebell P Journal article, Review article